@misc{oai:repo.qst.go.jp:00062696,
 author = {長谷部, 充彦 and 吉川, 京燦 and Ｓｈｅｒｉｆ, Ｍａｈｍｏｕｄ Ａｂｄ−Ｅｌｒａｚｅｋ Ｈｅｌｍｙ and 石川, 博之 and 佐合, 賢治 and 田村, 克巳 and 神立, 進 and 溝江, 純悦 and 佐賀, 恒夫 and 鈴木, 和年 and 辻井, 博彦 and 長谷部 充彦 and 吉川 京燦 and Ｓｈｅｒｉｆ Ｍａｈｍｏｕｄ Ａｂｄ−Ｅｌｒａｚｅｋ Ｈｅｌｍｙ and 石川 博之 and 佐合 賢治 and 田村 克巳 and 神立 進 and 溝江 純悦 and 佐賀 恒夫 and 鈴木 和年 and 辻井 博彦},
 month = {Apr},
 note = {PURPOSE: The purpose of this study is to assess the ability of C-11 methionine PET (MET-PET) to predict prognosis of patient with adenocarcinoma in head and neck treated by carbon ion radiotherapy (CIRT).
METHOD AND MATERIALS: We studied consecutive 23(male: 15, female: 8) patients with proven adenocarcinoma in head and neck who had been referred to our hospital for CIRT. The average patient age was 61.9 years (range 40 to 82). Patients were followed for 5.1 to 89.8 months (mean: 31.9 months) after CIRT. We evaluated the lesion semi-quantitatively on the basis of the Tumor-to-Normal-tissue Ratio (TNR). We statistically analyzed the relationship between tumor MET uptake level at pre and post CIRT.
RESULTS: There were significant relationships between the level of tumor activity before CIRT and patients prognosis, recurrence and metastasis rate (p=0.029, 0.043, and 0.014) from Kaplan-Meier analysis. The level of tumor activity after CIRT also significantly related to patients prognosis, recurrence and metastasis rate (p=0.049, 0.043, and 0.014). No statistically significant relationship was observed between tumor uptake change after CIRT and survival rate.
CONCLUSIONS:MET-PET is useful to predict patients survival rate, recurrence and metastasis rate in patients with head and neck adenocarcinoma treated by CIRT., H19年度HIMAC共同利用研究成果発表会},
 title = {頭頸部領域腺癌系腫瘍のメチオニンPETによる重粒子線治療予後評価の研究},
 year = {2008}
}